Cost-Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Cancer Treatment: A Systematic Review

Background: PARP inhibitors have shown significant improvement in progression-free survival, but their costs cast a considerable financial burden. In line with value-based oncology, it is important to evaluate whether drug prices justify the outcomes. Objectives: The aim of the study was to systemat...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Vivien Kin Yi, Yang, Runqing, Wong, Ian Chi Kei, Li, Xue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313592/
https://www.ncbi.nlm.nih.gov/pubmed/35899114
http://dx.doi.org/10.3389/fphar.2022.891149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313592/
https://www.ncbi.nlm.nih.gov/pubmed/35899114
http://dx.doi.org/10.3389/fphar.2022.891149

Ejemplares similares